Analysis of Therapeutic Effect of Lianhua Qingwen on Acute Upper Respiratory Tract Infection

CAI Renjie; PENG Sujuan

doi:10.13919/j.issn.2095-6274.ZHJY202404003

Abstract：Objective To explore the effect and analysis of treating upper respiratory tract infection pa-tients with Lianhua Qingwen in addition to symptomatic in the emergency department.Methods 100 patients with upper respiratory tract infections from January 2022 to January 2023 were divided into two groups(the control group and the study group)according to the principle of randomization,with 50 cases in each group.Both groups received conventional symptomatic treatment.On this basis,the study group adopted Lianhua Qingwen capsule for treatment.The changes of inflammatory factors[interleukin-6(IL-6),hypersensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)],immune function indicators(IgA,IgM,IgG)before and after treatment,and the duration of clinical symptom remission of the two groups were observed.Results There were no significant differences in the levels of hs-CRP,IL-6,TNF-α,IgA,IgM,and IgG between the two groups before treatment(P＞0.05).The levels of IL-6,hs-CRP,TNF-α,IgA,and IgM after treatment in the study group were lower than those in the control group,but the IgG levels after treatment of the study group were significantly higher than that of the control group.The duration of relief of cough,fever,nasal congestion,and sore throat in the study group was shorter than those in the control group,P＜0.05.Conclusion Patients with acute respiratory diseases can be treated with Lianhua Qingwen for more significant effect,which can reduce the inflammatory response of patients,improve the immune function of patients,and promote the remission of clinical symptoms.